BETHESDA, Md.--Scientists at the National Cancer Institute (NCI), the largest of the 17 biomedical research centers operated by the US National Institutes of Health, have spent the past decade crafting a bioinformatics program to facilitate the institute's efforts to discover cancer cures.

Since 1990, NCI has tested more than 70,000 compounds for activity against 60 cancer cell lines. At least 5 have entered human trials. More than 460,000 other compounds await testing. Along the way, NCI has developed an arsenal of diverse genomics-based drug discovery tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.